• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague

byAstrid BradshawandAlisha Yi
August 21, 2025
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM. 

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

Patient Basics: Plague (Yersinia Pestis)

Tags: aminoglycosideaminoglycoside-ciprofloxacinbubonic plagueciprofloxacinPlague
Previous Post

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

Next Post

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
All Specialties

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

August 28, 2025
Publication of pneumonia antibiotic guidelines changed prescribing trends
Infectious Disease

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

December 18, 2019
Health A to Z

Patient Basics: Plague (Yersinia Pestis)

November 30, 2014
Next Post
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

Incidental findings common with breast imaging, often benign

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors in the Initial Resuscitation of Patients With Severe Trauma: The FiiRST-2 Randomized Clinical Trial
  • Antioxidant Treatment and the Chance to Conceive in Men Seeking Fertility Care: The SUMMER Randomized Clinical Trial
  • DAWN Trial: Redefining the Treatment Window for Stroke Thrombectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.